Aehr Test Systems (AEHR) is back on traders’ radars after securing a record US$41 million order from an existing hyperscale AI customer, along with a backlog that nearly doubled year over year.

Despite a 5.65% one day share price pullback to US$91.26 as traders react to mixed earnings and recent equity issuance, Aehr’s 30 day share price return of 81.61% and very large 1 year total shareholder return suggest momentum is still firmly positive.

If you are looking for more AI related opportunities beyond Aehr’s testing focus, this is a good moment to scan 40 AI infrastructure stocks for potential candidates riding similar demand trends.

With the stock up 81.61% in the last month and more than 9x over the past year, alongside a record US$41 million AI order, the key question now is whether Aehr is still mispriced or if the market is already paying for tomorrow’s growth.

Most Popular Narrative: 399.5% Overvalued

According to Arkus, the most followed narrative estimates Aehr’s fair value at $18.27, which is far below the last close at $91.26. This creates a sharp valuation gap.

AEHR may still have attractive technology and exposure to semiconductor growth markets. But the capital allocation record deserves as much scrutiny as the product story.

For shareholders, the real story may not be burn-in systems or AI demand.

Want to see how a high growth outlook, ongoing losses, and insider behavior all connect to that fair value estimate? The narrative links revenue forecasts, margins, and dilution in a way the share price currently does not spell out.

Result: Fair Value of $18.27 (OVERVALUED)

However, a US$41 million AI order and strong recent share price momentum could challenge the overvaluation thesis if they translate into sustained demand and stronger profitability.

Next Steps

With such split views around Aehr’s potential, this is the moment to move fast, review the data yourself, and weigh both the upside and the red flags highlighted in the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If Aehr feels fully priced or outside your comfort zone, broaden your watchlist now using focused stock lists that surface different types of potential opportunities.

• Target quality at a discount by scanning companies highlighted in the 51 high quality undervalued stocks before others catch on.
• Strengthen your income stream by reviewing the 12 dividend fortresses that could add reliable yield to your portfolio.
• Prioritize resilience by studying the 72 resilient stocks with low risk scores that may better fit a capital preservation mindset.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.